1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
1 of 3
FEATURED COMPANIES
- Akorn Inc.
- Allergan Plc
- Bayer AG
- Daiichi Sankyo Co. Ltd.
- GlaxoSmithKline Plc
- Novartis AG
- MORE
Global Eye Infections Therapeutics Market: About this market
The eye infections therapeutics market analysis considers sales from conjunctivitis, keratitis, blepharitis, and other eye infections types. Our analysis also considers the sales of eye infections therapeutics in Asia, Europe, North America, and ROW. In 2018, the conjunctivitis segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the growing awareness about eye infections will play a significant role in the conjunctivitis segment to maintain its market position. Also, our global eye infections therapeutics market report looks at factors such as the rising geriatric population, high prevalence, and incidence of eye infections, and growing healthcare expenditure. However, patent expiry of blockbuster drugs, side effects associated with antibiotics, and stringent regulatory guidelines may hamper the growth of the eye infections therapeutics industry over the forecast period.
Global Eye Infections Therapeutics Market: Overview
Rising geriatric population
The geriatric population is more prone to ophthalmic problems because people are more vulnerable to eye infections as they age. Although eye infections account for a considerable proportion of these ophthalmic problems, there is a little clinical information in studies on infections, such as conjunctivitis and keratitis, among the elderly. Eye infection patients aged over 60 years generally need special medical attention as the condition can become more severe at that age. These factors will lead to the expansion of the global eye infections therapeutics market at a CAGR of almost 3% during the forecast period.
Growing adoption of generics
The consumption of generic drugs is gaining prominence in the market as the regulatory approval of these drugs is equally stringent as that for branded drugs. Generic drugs do not undergo clinical trials on animals and humans. This has significantly reduced the cost of generic drugs. Many patients and doctors are increasing their preference for generic drugs. In addition, they are identical to branded drugs in terms of intended use, route of administration, dosage, quality, strength, and price. They also contain similar benefits and active ingredients as their branded counterparts. These factors are encouraging the adoption of generic drugs for eye infections which will have a positive impact on the overall market growth.
Competitive Landscape
With the presence of several major players, the global eye infections therapeutics market is highly fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading eye infections therapeutics manufacturers, that include Akorn Inc., Allergan Plc, Bausch Health Companies Inc., Bayer AG, Daiichi Sankyo Co. Ltd., GlaxoSmithKline Plc, Novartis AG, Pfizer Inc., Sanofi, and Santen Pharmaceutical Co. Ltd.
Also, the eye infections therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
The eye infections therapeutics market analysis considers sales from conjunctivitis, keratitis, blepharitis, and other eye infections types. Our analysis also considers the sales of eye infections therapeutics in Asia, Europe, North America, and ROW. In 2018, the conjunctivitis segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the growing awareness about eye infections will play a significant role in the conjunctivitis segment to maintain its market position. Also, our global eye infections therapeutics market report looks at factors such as the rising geriatric population, high prevalence, and incidence of eye infections, and growing healthcare expenditure. However, patent expiry of blockbuster drugs, side effects associated with antibiotics, and stringent regulatory guidelines may hamper the growth of the eye infections therapeutics industry over the forecast period.
Global Eye Infections Therapeutics Market: Overview
Rising geriatric population
The geriatric population is more prone to ophthalmic problems because people are more vulnerable to eye infections as they age. Although eye infections account for a considerable proportion of these ophthalmic problems, there is a little clinical information in studies on infections, such as conjunctivitis and keratitis, among the elderly. Eye infection patients aged over 60 years generally need special medical attention as the condition can become more severe at that age. These factors will lead to the expansion of the global eye infections therapeutics market at a CAGR of almost 3% during the forecast period.
Growing adoption of generics
The consumption of generic drugs is gaining prominence in the market as the regulatory approval of these drugs is equally stringent as that for branded drugs. Generic drugs do not undergo clinical trials on animals and humans. This has significantly reduced the cost of generic drugs. Many patients and doctors are increasing their preference for generic drugs. In addition, they are identical to branded drugs in terms of intended use, route of administration, dosage, quality, strength, and price. They also contain similar benefits and active ingredients as their branded counterparts. These factors are encouraging the adoption of generic drugs for eye infections which will have a positive impact on the overall market growth.
Competitive Landscape
With the presence of several major players, the global eye infections therapeutics market is highly fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading eye infections therapeutics manufacturers, that include Akorn Inc., Allergan Plc, Bausch Health Companies Inc., Bayer AG, Daiichi Sankyo Co. Ltd., GlaxoSmithKline Plc, Novartis AG, Pfizer Inc., Sanofi, and Santen Pharmaceutical Co. Ltd.
Also, the eye infections therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
2 of 3
FEATURED COMPANIES
- Akorn Inc.
- Allergan Plc
- Bayer AG
- Daiichi Sankyo Co. Ltd.
- GlaxoSmithKline Plc
- Novartis AG
- MORE
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
2.1 Preface
2.2 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
PART 10: DRIVERS AND CHALLENGES
Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Type - Market share 2018-2023 (%)
Exhibit 19: Comparison by type
Exhibit 20: Conjunctivitis - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Conjunctivitis - Year-over-year growth 2019-2023 (%)
Exhibit 22: Keratitis - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Keratitis - Year-over-year growth 2019-2023 (%)
Exhibit 24: Blepharitis - Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Blepharitis - Year-over-year growth 2019-2023 (%)
Exhibit 26: Other eye infections - Market size and forecast 2018-2023 ($ millions)
Exhibit 27: Other eye infections - Year-over-year growth 2019-2023 (%)
Exhibit 28: Market opportunity by type
Exhibit 29: Customer landscape
Exhibit 30: Market share by geography 2018-2023 (%)
Exhibit 31: Geographic comparison
Exhibit 32: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: North America - Year-over-year growth 2019-2023 (%)
Exhibit 34: Top 3 countries in North America
Exhibit 35: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 37: Top 3 countries in Europe
Exhibit 38: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 39: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 40: Top 3 countries in Asia
Exhibit 41: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 42: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 43: Top 3 countries in ROW
Exhibit 44: Key leading countries
Exhibit 45: Market opportunity
Exhibit 46: Impact of drivers and challenges
Exhibit 47: Vendor landscape
Exhibit 48: Landscape disruption
Exhibit 49: Vendors covered
Exhibit 50: Vendor classification
Exhibit 51: Market positioning of vendors
Exhibit 52: Akorn Inc. - Vendor overview
Exhibit 53: Akorn Inc. - Business segments
Exhibit 54: Akorn Inc. - Organizational developments
Exhibit 55: Akorn Inc. - Segment focus
Exhibit 56: Akorn Inc. - Key offerings
Exhibit 57: Akorn Inc. - Key customers
Exhibit 58: Allergan Plc - Vendor overview
Exhibit 59: Allergan Plc - Product segments
Exhibit 60: Allergan Plc - Organizational developments
Exhibit 61: Allergan Plc - Segment focus
Exhibit 62: Allergan Plc - Key offerings
Exhibit 63: Allergan Plc - Key customers
Exhibit 64: Bausch Health Companies Inc. - Vendor overview
Exhibit 65: Bausch Health Companies Inc. - Business segments
Exhibit 66: Bausch Health Companies Inc. - Organizational developments
Exhibit 67: Bausch Health Companies Inc. - Geographic focus
Exhibit 68: Bausch Health Companies Inc. - Segment focus
Exhibit 69: Bausch Health Companies Inc. - Key offerings
Exhibit 70: Bausch Health Companies Inc. - Key customers
Exhibit 71: Bayer AG - Vendor overview
Exhibit 72: Bayer AG - Business segments
Exhibit 73: Bayer AG - Organizational developments
Exhibit 74: Bayer AG - Geographic focus
Exhibit 75: Bayer AG - Segment focus
Exhibit 76: Bayer AG - Key offerings
Exhibit 77: Bayer AG - Key customers
Exhibit 78: Daiichi Sankyo Co. Ltd. - Vendor overview
Exhibit 79: Daiichi Sankyo Co. Ltd. - Business segments
Exhibit 80: Daiichi Sankyo Co. Ltd. - Organizational developments
Exhibit 81: Daiichi Sankyo Co. Ltd. - Geographic focus
Exhibit 82: Daiichi Sankyo Co. Ltd. - Key offerings
Exhibit 83: Daiichi Sankyo Co. Ltd. - Key customers
Exhibit 84: GlaxoSmithKline Plc - Vendor overview
Exhibit 85: GlaxoSmithKline Plc - Business segments
Exhibit 86: GlaxoSmithKline Plc - Organizational developments
Exhibit 87: GlaxoSmithKline Plc - Geographic focus
Exhibit 88: GlaxoSmithKline Plc - Segment focus
Exhibit 89: GlaxoSmithKline Plc - Key offerings
Exhibit 90: GlaxoSmithKline Plc - Key customers
Exhibit 91: Novartis AG - Vendor overview
Exhibit 92: Novartis AG - Business segments
Exhibit 93: Novartis AG - Organizational developments
Exhibit 94: Novartis AG - Geographic focus
Exhibit 95: Novartis AG - Segment focus
Exhibit 96: Novartis AG - Key offerings
Exhibit 97: Novartis AG - Key customers
Exhibit 98: Pfizer Inc. - Vendor overview
Exhibit 99: Pfizer Inc. - Business segments
Exhibit 100: Pfizer Inc. - Organizational developments
Exhibit 101: Pfizer Inc. - Geographic focus
Exhibit 102: Pfizer Inc. - Segment focus
Exhibit 103: Pfizer Inc. - Key offerings
Exhibit 104: Pfizer Inc. - Key customers
Exhibit 105: Sanofi - Vendor overview
Exhibit 106: Sanofi - Business segment
Exhibit 107: Sanofi - Organizational developments
Exhibit 108: Sanofi - Geographic focus
Exhibit 109: Sanofi - Segment focus
Exhibit 110: Sanofi - Key offerings
Exhibit 111: Sanofi - Key customers
Exhibit 112: Santen Pharmaceutical Co. Ltd. - Vendor overview
Exhibit 113: Santen Pharmaceutical Co. Ltd. - Business segments
Exhibit 114: Santen Pharmaceutical Co. Ltd. - Organizational developments
Exhibit 115: Santen Pharmaceutical Co. Ltd. - Geographic focus
Exhibit 116: Santen Pharmaceutical Co. Ltd. - Segment focus
Exhibit 117: Santen Pharmaceutical Co. Ltd. - Key offerings
Exhibit 118: Santen Pharmaceutical Co. Ltd. - Key customers
Exhibit 119: Validation techniques employed for market sizing
Exhibit 120: Definition of market positioning of vendors
PART 02: SCOPE OF THE REPORT
2.1 Preface
2.2 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
- Market segmentation by type
- Comparison by type
- Conjunctivitis - Market size and forecast 2018-2023
- Keratitis - Market size and forecast 2018-2023
- Blepharitis - Market size and forecast 2018-2023
- Other eye infections - Market size and forecast 2018-2023
- Market opportunity by type
PART 08: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2018-2023
- Europe - Market size and forecast 2018-2023
- Asia - Market size and forecast 2018-2023
- ROW - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 10: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
- Rising number of government initiatives
- Growing adoption of generics
- Saturation in the pipeline landscape
- Overview
- Landscape disruption
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Akorn Inc.
- Allergan Plc
- Bausch Health Companies Inc.
- Bayer AG
- Daiichi Sankyo Co. Ltd.
- GlaxoSmithKline Plc
- Novartis AG
- Pfizer Inc.
- Sanofi
- Santen Pharmaceutical Co. Ltd.
- Research methodology
- List of abbreviations
- Definition of market positioning of vendors
Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Type - Market share 2018-2023 (%)
Exhibit 19: Comparison by type
Exhibit 20: Conjunctivitis - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Conjunctivitis - Year-over-year growth 2019-2023 (%)
Exhibit 22: Keratitis - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Keratitis - Year-over-year growth 2019-2023 (%)
Exhibit 24: Blepharitis - Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Blepharitis - Year-over-year growth 2019-2023 (%)
Exhibit 26: Other eye infections - Market size and forecast 2018-2023 ($ millions)
Exhibit 27: Other eye infections - Year-over-year growth 2019-2023 (%)
Exhibit 28: Market opportunity by type
Exhibit 29: Customer landscape
Exhibit 30: Market share by geography 2018-2023 (%)
Exhibit 31: Geographic comparison
Exhibit 32: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: North America - Year-over-year growth 2019-2023 (%)
Exhibit 34: Top 3 countries in North America
Exhibit 35: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 37: Top 3 countries in Europe
Exhibit 38: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 39: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 40: Top 3 countries in Asia
Exhibit 41: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 42: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 43: Top 3 countries in ROW
Exhibit 44: Key leading countries
Exhibit 45: Market opportunity
Exhibit 46: Impact of drivers and challenges
Exhibit 47: Vendor landscape
Exhibit 48: Landscape disruption
Exhibit 49: Vendors covered
Exhibit 50: Vendor classification
Exhibit 51: Market positioning of vendors
Exhibit 52: Akorn Inc. - Vendor overview
Exhibit 53: Akorn Inc. - Business segments
Exhibit 54: Akorn Inc. - Organizational developments
Exhibit 55: Akorn Inc. - Segment focus
Exhibit 56: Akorn Inc. - Key offerings
Exhibit 57: Akorn Inc. - Key customers
Exhibit 58: Allergan Plc - Vendor overview
Exhibit 59: Allergan Plc - Product segments
Exhibit 60: Allergan Plc - Organizational developments
Exhibit 61: Allergan Plc - Segment focus
Exhibit 62: Allergan Plc - Key offerings
Exhibit 63: Allergan Plc - Key customers
Exhibit 64: Bausch Health Companies Inc. - Vendor overview
Exhibit 65: Bausch Health Companies Inc. - Business segments
Exhibit 66: Bausch Health Companies Inc. - Organizational developments
Exhibit 67: Bausch Health Companies Inc. - Geographic focus
Exhibit 68: Bausch Health Companies Inc. - Segment focus
Exhibit 69: Bausch Health Companies Inc. - Key offerings
Exhibit 70: Bausch Health Companies Inc. - Key customers
Exhibit 71: Bayer AG - Vendor overview
Exhibit 72: Bayer AG - Business segments
Exhibit 73: Bayer AG - Organizational developments
Exhibit 74: Bayer AG - Geographic focus
Exhibit 75: Bayer AG - Segment focus
Exhibit 76: Bayer AG - Key offerings
Exhibit 77: Bayer AG - Key customers
Exhibit 78: Daiichi Sankyo Co. Ltd. - Vendor overview
Exhibit 79: Daiichi Sankyo Co. Ltd. - Business segments
Exhibit 80: Daiichi Sankyo Co. Ltd. - Organizational developments
Exhibit 81: Daiichi Sankyo Co. Ltd. - Geographic focus
Exhibit 82: Daiichi Sankyo Co. Ltd. - Key offerings
Exhibit 83: Daiichi Sankyo Co. Ltd. - Key customers
Exhibit 84: GlaxoSmithKline Plc - Vendor overview
Exhibit 85: GlaxoSmithKline Plc - Business segments
Exhibit 86: GlaxoSmithKline Plc - Organizational developments
Exhibit 87: GlaxoSmithKline Plc - Geographic focus
Exhibit 88: GlaxoSmithKline Plc - Segment focus
Exhibit 89: GlaxoSmithKline Plc - Key offerings
Exhibit 90: GlaxoSmithKline Plc - Key customers
Exhibit 91: Novartis AG - Vendor overview
Exhibit 92: Novartis AG - Business segments
Exhibit 93: Novartis AG - Organizational developments
Exhibit 94: Novartis AG - Geographic focus
Exhibit 95: Novartis AG - Segment focus
Exhibit 96: Novartis AG - Key offerings
Exhibit 97: Novartis AG - Key customers
Exhibit 98: Pfizer Inc. - Vendor overview
Exhibit 99: Pfizer Inc. - Business segments
Exhibit 100: Pfizer Inc. - Organizational developments
Exhibit 101: Pfizer Inc. - Geographic focus
Exhibit 102: Pfizer Inc. - Segment focus
Exhibit 103: Pfizer Inc. - Key offerings
Exhibit 104: Pfizer Inc. - Key customers
Exhibit 105: Sanofi - Vendor overview
Exhibit 106: Sanofi - Business segment
Exhibit 107: Sanofi - Organizational developments
Exhibit 108: Sanofi - Geographic focus
Exhibit 109: Sanofi - Segment focus
Exhibit 110: Sanofi - Key offerings
Exhibit 111: Sanofi - Key customers
Exhibit 112: Santen Pharmaceutical Co. Ltd. - Vendor overview
Exhibit 113: Santen Pharmaceutical Co. Ltd. - Business segments
Exhibit 114: Santen Pharmaceutical Co. Ltd. - Organizational developments
Exhibit 115: Santen Pharmaceutical Co. Ltd. - Geographic focus
Exhibit 116: Santen Pharmaceutical Co. Ltd. - Segment focus
Exhibit 117: Santen Pharmaceutical Co. Ltd. - Key offerings
Exhibit 118: Santen Pharmaceutical Co. Ltd. - Key customers
Exhibit 119: Validation techniques employed for market sizing
Exhibit 120: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
3 of 3
LOADING...
4 of 3
- Akorn Inc.
- Allergan Plc
- Bausch Health Companies, Inc.
- Bayer AG
- Daiichi Sankyo Co. Ltd.
- GlaxoSmithKline Plc
- Novartis AG
- Pfizer Inc.
- Sanofi
- Santen Pharmaceutical Co. Ltd.
Note: Product cover images may vary from those shown
